tetano
Editor, Senior Moderator
Allergy Rhinol (Providence)
. 2022 Apr 25;13:21526575221096044.
doi: 10.1177/21526575221096044. eCollection Jan-Dec 2022.
COVID-19 Infection in Patients with Humoral Immunodeficiency: A Case Series and Literature Review
Maaz Jalil[SUP] 1 [/SUP], Julianne Pietras[SUP] 2 [/SUP], Syed N Ahmed[SUP] 2 [/SUP], Phuong Daniels[SUP] 2 [/SUP], Robert Hostoffer[SUP] 1 3 [/SUP]
Affiliations
Abstract
Background: The coronavirus 2019 disease (COVID-19) has infected many individuals worldwide and continues to pose a significant threat to those with weakened immune systems. The data evaluating the clinical outcomes of patients with humoral immunodeficiencies that contract COVID-19 is limited and conflicting.
Objective: To describe the clinical outcomes of COVID-19 infections in patients with primary humoral immunodeficiency and compare results to current literature.
Methods: We conducted a retrospective cohort review on 15 patients with a humoral immunodeficiency defined as Common Variable Immunodeficiency, Specific Antibody Deficiency, or unspecified hypogammaglobulinemia, who contracted COVID-19. Severity scores were determined to evaluate the clinical outcomes of these patients.
Results: Of our 15-patient cohort, 33% of individuals with a humoral immunodeficiency infected with COVID-19 had moderate to severe disease, requiring hospitalization or resulting in death. COVID-19 mortality rate was found to be 7%. All 5 of our patients with severe COVID-19 infection had at least 1 comorbidity or risk factor.
Conclusion: Within our cohort of humoral immunodeficient patients infected with COVID-19, we found a higher rate of moderate to severe COVID-19 infection and worse clinical outcomes, particularly in patients with comorbidities or risk factors.
Keywords: COVID-19; CVID; SARS-CoV-2; coronavirus; immunodeficiency; primary.
. 2022 Apr 25;13:21526575221096044.
doi: 10.1177/21526575221096044. eCollection Jan-Dec 2022.
COVID-19 Infection in Patients with Humoral Immunodeficiency: A Case Series and Literature Review
Maaz Jalil[SUP] 1 [/SUP], Julianne Pietras[SUP] 2 [/SUP], Syed N Ahmed[SUP] 2 [/SUP], Phuong Daniels[SUP] 2 [/SUP], Robert Hostoffer[SUP] 1 3 [/SUP]
Affiliations
- PMID: 35496893
- PMCID: PMC9047039
- DOI: 10.1177/21526575221096044
Abstract
Background: The coronavirus 2019 disease (COVID-19) has infected many individuals worldwide and continues to pose a significant threat to those with weakened immune systems. The data evaluating the clinical outcomes of patients with humoral immunodeficiencies that contract COVID-19 is limited and conflicting.
Objective: To describe the clinical outcomes of COVID-19 infections in patients with primary humoral immunodeficiency and compare results to current literature.
Methods: We conducted a retrospective cohort review on 15 patients with a humoral immunodeficiency defined as Common Variable Immunodeficiency, Specific Antibody Deficiency, or unspecified hypogammaglobulinemia, who contracted COVID-19. Severity scores were determined to evaluate the clinical outcomes of these patients.
Results: Of our 15-patient cohort, 33% of individuals with a humoral immunodeficiency infected with COVID-19 had moderate to severe disease, requiring hospitalization or resulting in death. COVID-19 mortality rate was found to be 7%. All 5 of our patients with severe COVID-19 infection had at least 1 comorbidity or risk factor.
Conclusion: Within our cohort of humoral immunodeficient patients infected with COVID-19, we found a higher rate of moderate to severe COVID-19 infection and worse clinical outcomes, particularly in patients with comorbidities or risk factors.
Keywords: COVID-19; CVID; SARS-CoV-2; coronavirus; immunodeficiency; primary.